# An Open-label Extension Study of Certolizumab Pegol in Chinese Patients With Rheumatoid Arthritis Who Enrolled in RA0044

> **NCT02319642** · PHASE3 · COMPLETED · sponsor: **UCB Pharma SA** · enrollment: 347 (actual)

## Conditions studied

- Rheumatoid Arthritis

## Interventions

- **DRUG:** Certolizumab Pegol

## Key facts

- **NCT ID:** NCT02319642
- **Lead sponsor:** UCB Pharma SA
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2014-11
- **Primary completion:** 2016-12
- **Final completion:** 2016-12
- **Target enrollment:** 347 (ACTUAL)
- **Last updated:** 2018-10-16

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02319642

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02319642, "An Open-label Extension Study of Certolizumab Pegol in Chinese Patients With Rheumatoid Arthritis Who Enrolled in RA0044". Retrieved via AI Analytics 2026-06-04 from https://api.ai-analytics.org/clinical/NCT02319642. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*